SyB L-1101

DRUG2 trials

Sponsors

SymBio Pharmaceuticals

Conditions

Myelodysplastic Syndrome

Phase 1

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

CompletedNCT01700335

SymBio PharmaceuticalsMyelodysplastic Syndrome

Start: 2012-06-30End: 2015-02-28Updated: 2022-11-21

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

CompletedNCT02000154

SymBio PharmaceuticalsMyelodysplastic Syndrome

Start: 2014-12-31End: 2015-05-31Updated: 2017-03-31